PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2241187-7	1990	However NAG index rose remarkably when CDDP was treated by CDDP.	Cisplatin	39-43	N-acetyl-alpha-glucosaminidase	Homo sapiens	8-11	
2241187-7	1990	However NAG index rose remarkably when CDDP was treated by CDDP.	Cisplatin	59-63	N-acetyl-alpha-glucosaminidase	Homo sapiens	8-11	
2316078-2	1990	Following prospective randomization, we examined NAG excretion during cisplatin treatment with/without nephroprotection, after intravenous urography with ionic/non-ionic contrast media, during lower/upper urinary tract infections and before/after extracorporeal shockwave lithotripsy for intrarenal calculi (first-generation equipment used).	Cisplatin	70-79	N-acetyl-alpha-glucosaminidase	Homo sapiens	49-52	
2316078-6	1990	However, the increase in NAG excretion was less impressive during cisplatin therapy when nephroprotective amino acids were infused, and in the urography group when non-ionic contrast media were used.	Cisplatin	66-75	N-acetyl-alpha-glucosaminidase	Homo sapiens	25-28	
6127169-4	1982	There was a significant increase in the urinary excretion of both enzymes (AAP and NAG) within 2 days of cis-platinum administration (NAG P less than 0.05 and AAP P less than 0.07).	Cisplatin	105-117	N-acetyl-alpha-glucosaminidase	Homo sapiens	83-86	
6127169-4	1982	There was a significant increase in the urinary excretion of both enzymes (AAP and NAG) within 2 days of cis-platinum administration (NAG P less than 0.05 and AAP P less than 0.07).	Cisplatin	105-117	N-acetyl-alpha-glucosaminidase	Homo sapiens	134-137	
11763992-11	2001	Moreover, the first course morning cisplatin and furosemide treatment was associated with less change in NAG excretion (less kidney toxicity) than the first course of evening cisplatin and furosemide treatment.	Cisplatin	35-44	N-acetyl-alpha-glucosaminidase	Homo sapiens	105-108	
11763992-12	2001	The second course evening cisplatin and furosemide treatment was associated with an increase in NAG excretion compared to the first course of treatment, while morning cisplatin and furosemide treatment in the second course showed less change in NAG excretion compared to the first course.	Cisplatin	26-35	N-acetyl-alpha-glucosaminidase	Homo sapiens	96-99	
29445029-13	2018	The decrease in GFRcysC and increase in N-acetyl-ss-glucosaminidase (NAG) and creatinine demonstrate that these biomarkers can quantify cisplatin glomerular and proximal tubular toxicity.	Cisplatin	136-145	N-acetyl-alpha-glucosaminidase	Homo sapiens	40-67	
29445029-13	2018	The decrease in GFRcysC and increase in N-acetyl-ss-glucosaminidase (NAG) and creatinine demonstrate that these biomarkers can quantify cisplatin glomerular and proximal tubular toxicity.	Cisplatin	136-145	N-acetyl-alpha-glucosaminidase	Homo sapiens	69-72